fluorouracil has been researched along with Genetic Predisposition in 72 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to evaluate the effect of potential regulatory variants in NLRC5 on overall survival and survival after 5-fluorouracil (5-FU)-based therapy of colorectal cancer (CRC) patients." | 7.88 | Short article: Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy. ( Catalano, C; da Silva Filho, MI; Försti, A; Hemminki, K; Jiraskova, K; Levy, M; Liska, V; Naccarati, A; Vodicka, P; Vodickova, L; Vycital, O; Vymetalkova, V; Weber, ANR, 2018) |
| "The most important cytotoxic drug namely, cyclophosphamide used in breast cancer along with epirubicin and 5-fluorouracil, is transported by ABCC transporters and detoxified by glutathione S-transferases (GSTs)." | 7.81 | Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients. ( Ahmed, MU; Bin Sayeed, MS; Hasnat, A; Hussain, SM; Islam, MS; Parvin, S; Uddin, MM, 2015) |
| " This gene codifies for the target enzyme of 5-fluorouracil (5-FU), the basic treatment in colorectal cancer." | 7.81 | Long Survival and Severe Toxicity Under 5-Fluorouracil-Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS. ( Balboa-Beltrán, E; Barros, F; Carracedo, A; Duran, G; Lamas, MJ, 2015) |
| "Hand-foot syndrome (HFS) is one of the most relevant dose-limiting adverse effects of capecitabine, an oral prodrug of 5-fluorouracil used in the standard treatment of breast and colorectal cancer." | 7.77 | A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. ( Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J, 2011) |
| "Chinese patients exhibit less irinotecan-related diarrhea due to higher frequence of UGT1A A1 * 28 wild genotype TA6/6." | 7.74 | [Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients]. ( Bao, HY; Jiao, SC; Li, F; Li, J; Shen, L; Song, ST; Wang, JW; Wang, Y; Xu, JM; Xu, N; Yang, L; Zhang, JS, 2007) |
| "A total of 91 ACC patients received capecitabine and oxaliplatin (CAPOX) as a part of a multicentre phase-III study of the Dutch Colorectal Cancer Group." | 5.14 | Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. ( Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Nortier, JW; Punt, CJ; Van der Straaten, T, 2009) |
| "To assess the predictive value of polymorphisms in dihydropyrimidine dehydrogenase (DPYD ), thymidylate synthase (TYMS ), and methylene tetrahydrofolate reductase (MTHFR ) and of nongenetic factors for severe leukopenia, diarrhea, and mucositis related to fluorouracil (FU) treatment." | 5.13 | Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. ( Blievernicht, J; Bokemeyer, C; Dippon, J; Eichelbaum, M; Fischer, J; Hofmann, U; Kerb, R; Klein, K; Marx, C; Schaeffeler, E; Schwab, M; Zanger, UM, 2008) |
| "We aimed to evaluate the effect of potential regulatory variants in NLRC5 on overall survival and survival after 5-fluorouracil (5-FU)-based therapy of colorectal cancer (CRC) patients." | 3.88 | Short article: Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy. ( Catalano, C; da Silva Filho, MI; Försti, A; Hemminki, K; Jiraskova, K; Levy, M; Liska, V; Naccarati, A; Vodicka, P; Vodickova, L; Vycital, O; Vymetalkova, V; Weber, ANR, 2018) |
| "The most important cytotoxic drug namely, cyclophosphamide used in breast cancer along with epirubicin and 5-fluorouracil, is transported by ABCC transporters and detoxified by glutathione S-transferases (GSTs)." | 3.81 | Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients. ( Ahmed, MU; Bin Sayeed, MS; Hasnat, A; Hussain, SM; Islam, MS; Parvin, S; Uddin, MM, 2015) |
| " This gene codifies for the target enzyme of 5-fluorouracil (5-FU), the basic treatment in colorectal cancer." | 3.81 | Long Survival and Severe Toxicity Under 5-Fluorouracil-Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS. ( Balboa-Beltrán, E; Barros, F; Carracedo, A; Duran, G; Lamas, MJ, 2015) |
| "A 71-year-old patient receiving combination chemotherapy (irinotecan, oxaliplatin and 5-fluorouracil (5-FU)) for metastatic pancreas cancer was admitted after her first cycle of chemotherapy with a severe and unexpectedly prolonged episode of neutropenic sepsis associated with pancytopenia and marked mucositis." | 3.80 | A rare cause of susceptibility to neutropenic sepsis in a patient with metastatic pancreas cancer. ( Gillmore, R; Suarez Martinez-Falero, B, 2014) |
| "Hand-foot syndrome (HFS) is one of the most relevant dose-limiting adverse effects of capecitabine, an oral prodrug of 5-fluorouracil used in the standard treatment of breast and colorectal cancer." | 3.77 | A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. ( Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J, 2011) |
| " To explore the predictability of TYMS polymorphisms for the sensitivity and toxicity of 5-fluorouracil (5-FU) in breast cancer patients, this study investigated the association between TYMS polymorphisms and TYMS protein expression in normal and tumour tissue specimens from 49 lymph node-positive breast cancer patients." | 3.76 | Relationship between thymidylate synthase (TYMS) gene polymorphism and TYMS protein levels in patients with high-risk breast cancer. ( Azumi, T; Fujishima, M; Hashimoto, Y; Hojo, T; Inui, H; Kato, H; Matsunami, N; Shiozaki, H; Watatani, M; Yamamoto, N; Yamato, M, 2010) |
| "Chinese patients exhibit less irinotecan-related diarrhea due to higher frequence of UGT1A A1 * 28 wild genotype TA6/6." | 3.74 | [Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients]. ( Bao, HY; Jiao, SC; Li, F; Li, J; Shen, L; Song, ST; Wang, JW; Wang, Y; Xu, JM; Xu, N; Yang, L; Zhang, JS, 2007) |
| " A total of 21 genetic variants were studied in 35 breast cancer patients treated with 5-FluoroUracil, mitomycin (FUMI) and in a similar cohort of 90 doxorubicin treated breast cancer patients." | 3.74 | Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival. ( Alnaes, GI; Børresen-Dale, AL; Hihn, B; Kristensen, VN; Liestøl, K; Lingjaerde, OC; Lønning, PE; Nordgard, SH; Sørlie, T; Tsalenko, A, 2008) |
| "Rs3817198(T > C) might result in breast carcinoma in individuals with BRCA1 and BRCA2 variants and can contribute to estrogen receptor (ER)-positive breast carcinoma." | 2.82 | The correlation of leukocyte-specific protein 1 (LSP1) rs3817198(T>C) polymorphism with breast cancer: A meta-analysis. ( Chen, J; Li, X; Li, Y; Liu, R; Liu, Z; Long, X; Xiao, Q; Xiong, H, 2022) |
| "We genotyped 306 patients with early breast cancer, who were randomised to receive post-operative radiotherapy or CMF chemotherapy, for the RAD51 135G>C polymorphism." | 2.80 | The RAD51 135G>C polymorphism is related to the effect of adjuvant therapy in early breast cancer. ( Asklid, A; Fornander, T; Söderlund Leifler, K; Stenmark Askmalm, M, 2015) |
| "Fluorouracil and cisplatin have been used most frequently as neoadjuvant therapy for esophageal cancer." | 2.79 | The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study. ( Ba-Ssalamah, A; Hejna, M; Kandioler, D; Kappel, S; Kührer, I; Mittlböck, M; Pluschnig, U; Schoppmann, SF; Wolf, B; Wrba, F; Zacherl, J; Zwrtek, R, 2014) |
| "In 2594 patients with complete adverse event (AE) data, the incidence of grade 3 or greater 5FU-AEs in DPYD*2A, I560S, and D949V carriers were 22/25 (88." | 2.79 | DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). ( Alberts, SR; Berenberg, JL; Diasio, RB; Goldberg, RM; Lee, AM; Pavey, E; Sargent, DJ; Shi, Q; Sinicrope, FA, 2014) |
| "The purpose of this study was to investigate the association between single nucleotide polymorphism (SNP) of CCND1 A870G and acute adverse events (AEs) in postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy (CRT)." | 2.78 | [Impact of CCND1 A870G polymorphism on acute adverse events in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy]. ( DU, ZL; Huang, Y; Jin, J; Li, YX; Lin, DX; Qiao, Y; Ren, H; Tan, W; Yu, DK, 2013) |
| "Breast cancer is one of the most common types of cancer diagnosed and the second leading cause of death among women." | 1.72 | Natural Compounds or Their Derivatives against Breast Cancer: A Computational Study. ( Butnariu, M; Calina, D; Cho, WC; Hossain, R; Islam, MS; Islam, MT; Khalipha, ABR; Khan, RA; Martorell, M; Ray, P; Sarkar, C; Sharifi-Rad, J; Umbetova, A, 2022) |
| " Severe (grade ≥III) toxicity in DPYD variant allele carriers receiving upfront FP dose reductions according to pharmacogenetic dosing guidelines and DPYD variant allele carriers not receiving FP dose reductions was compared with DPYD wild-type patients receiving standard dose of FPs in CRT." | 1.48 | Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. ( Cecchin, E; Dreussi, E; Fiocco, M; Gelderblom, H; Guchelaar, HJ; Henricks, LM; Lunenburg, CATC; Meulendijks, D; Peters, FP; Schellens, JHM; Swen, JJ; Toffoli, G, 2018) |
| "He subsequently developed sinusoidal obstruction syndrome (SOS) that resolved on discontinuation of XELOX treatment." | 1.43 | Genetic predisposition resulting in sinusoidal obstruction syndrome in a patient with resected sigmoid cancer on adjuvant oxaliplatin. ( Chan, SH; Koo, SX; Ngeow, J, 2016) |
| "dMMR rectal cancer had excellent prognosis and pathologic response with current multimodality therapy including an individualized surgical treatment plan." | 1.43 | DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics. ( Bednarski, B; Borras, E; Chang, GJ; de Rosa, N; Feig, BW; Krishnan, S; Lynch, PM; Messick, CA; Rodriguez-Bigas, MA; Skibber, JM; Veerapong, J; Vilar, E; You, YN, 2016) |
| "We showed a higher risk of breast cancer occurrence for the Trp allele and the Arg194Trp genotype of the XRCC1 gene." | 1.39 | Association of the Arg194Trp and the Arg399Gln polymorphisms of the XRCC1 gene with risk occurrence and the response to adjuvant therapy among Polish women with breast cancer. ( Kordek, R; Kusinska, R; Majsterek, I; Przybylowska-Sygut, K; Stanczyk, M, 2013) |
| "Our results show compelling evidence that, at least in distinct tumor types, a common DPYD polymorphism strongly contributes to the occurrence of fluoropyrimidine-related drug adverse effects." | 1.35 | Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. ( Busse, B; Gross, E; Kiechle, M; Klein, HG; Lordick, F; Meindl, A; Neubauer, S; Riemenschneider, M; Seck, K, 2008) |
| "All cases of breast carcinoma diagnosed during the period from 1989 to 2001 were retrospectively reviewed." | 1.34 | [Diagnosis and prognosis study of breast carcinoma with micropapillary component]. ( Chen, L; Fan, Y; Fu, L; Guo, XJ; Lang, RG; Sun, YL, 2007) |
| "Colon cancer (CC) in hereditary nonpolyposis colorectal cancer (HNPCC) is due to a dysfunctioning MMR gene that leads to microsatellite instability (MSI)." | 1.32 | Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. ( Cats, A; de Vos tot Nederveen Cappel, WH; Gelderblom, H; Griffioen, G; Kleibeuker, JH; Menko, FH; Meulenbeld, HJ; Morreau, H; Nagengast, FM; Vasen, HF, 2004) |
| "Demyelination was accelerated in infected animals treated with these agents at 45 days but at 70 days a significant difference in extent of demyelination was no longer appreciated between treatment and control groups." | 1.30 | 5-Fluorouracil and levamisole exacerbate demyelination in susceptible mice infected with Theiler's virus. ( Kimmel, DW; Lucchinetti, CF; Pavelko, K; Rodriguez, M, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.39) | 18.2507 |
| 2000's | 20 (27.78) | 29.6817 |
| 2010's | 44 (61.11) | 24.3611 |
| 2020's | 7 (9.72) | 2.80 |
| Authors | Studies |
|---|---|
| Hossain, R | 1 |
| Ray, P | 1 |
| Sarkar, C | 1 |
| Islam, MS | 3 |
| Khan, RA | 1 |
| Khalipha, ABR | 1 |
| Islam, MT | 1 |
| Cho, WC | 1 |
| Martorell, M | 1 |
| Sharifi-Rad, J | 1 |
| Butnariu, M | 1 |
| Umbetova, A | 1 |
| Calina, D | 1 |
| Chen, J | 4 |
| Xiao, Q | 3 |
| Li, X | 3 |
| Liu, R | 4 |
| Long, X | 3 |
| Liu, Z | 3 |
| Xiong, H | 3 |
| Li, Y | 3 |
| Yılmaz, A | 1 |
| Mirili, C | 1 |
| Bilici, M | 1 |
| Tekin, SB | 1 |
| Maniglia, MP | 1 |
| Russo, A | 2 |
| Biselli-Chicote, PM | 1 |
| Oliveira-Cucolo, JG | 1 |
| Rodrigues-Fleming, GH | 1 |
| -Maniglia, JV | 1 |
| Pavarino, ÉC | 1 |
| Goloni-Bertollo, EM | 1 |
| Pazderová, N | 1 |
| Urbán, V | 1 |
| Makovník, M | 1 |
| Macák, D | 1 |
| Janega, P | 1 |
| Chovanec, M | 1 |
| Rejleková, K | 1 |
| Mardiak, J | 1 |
| Mego, M | 1 |
| Ramos-Esquivel, A | 1 |
| Chinchilla-Monge, R | 1 |
| Abbas, J | 1 |
| Valle, M | 1 |
| Schneiderova, M | 1 |
| Naccarati, A | 2 |
| Pardini, B | 1 |
| Rosa, F | 1 |
| Gaetano, CD | 1 |
| Jiraskova, K | 2 |
| Opattova, A | 1 |
| Levy, M | 2 |
| Veskrna, K | 1 |
| Veskrnova, V | 1 |
| Buchler, T | 1 |
| Landi, S | 1 |
| Vodicka, P | 2 |
| Vymetalkova, V | 2 |
| Catalano, C | 1 |
| da Silva Filho, MI | 1 |
| Liska, V | 1 |
| Vycital, O | 1 |
| Vodickova, L | 1 |
| Hemminki, K | 1 |
| Weber, ANR | 1 |
| Försti, A | 1 |
| Lunenburg, CATC | 1 |
| Henricks, LM | 2 |
| Dreussi, E | 1 |
| Peters, FP | 1 |
| Fiocco, M | 1 |
| Meulendijks, D | 2 |
| Toffoli, G | 1 |
| Guchelaar, HJ | 2 |
| Swen, JJ | 1 |
| Cecchin, E | 1 |
| Schellens, JHM | 1 |
| Gelderblom, H | 3 |
| Jiménez Gordo, AM | 1 |
| López Gómez, M | 1 |
| Paula, DP | 1 |
| do Brasil Costa, VI | 1 |
| Jorge, RV | 1 |
| Nobre, FF | 1 |
| Robinson, SM | 1 |
| Mann, J | 1 |
| Manas, DM | 1 |
| Mann, DA | 1 |
| White, SA | 1 |
| Roselli, M | 1 |
| Ferroni, P | 1 |
| Rolfo, C | 1 |
| Peeters, M | 1 |
| Palmirotta, R | 1 |
| Formica, V | 1 |
| Ludovici, G | 1 |
| Laudisi, A | 1 |
| De Marchis, ML | 1 |
| La Farina, F | 1 |
| Guadagni, F | 1 |
| Stenholm, L | 1 |
| Stoehlmacher-Williams, J | 1 |
| Al-Batran, SE | 1 |
| Heussen, N | 1 |
| Akin, S | 1 |
| Pauligk, C | 1 |
| Lehmann, S | 1 |
| Senff, T | 1 |
| Hofheinz, RD | 1 |
| Ehninger, G | 1 |
| Kramer, M | 1 |
| Goekkurt, E | 2 |
| Qiao, Y | 1 |
| Ren, H | 1 |
| Huang, Y | 1 |
| DU, ZL | 1 |
| Yu, DK | 1 |
| Jin, J | 1 |
| Li, YX | 1 |
| Lin, DX | 1 |
| Tan, W | 1 |
| Suarez Martinez-Falero, B | 1 |
| Gillmore, R | 1 |
| Ulrich, CM | 2 |
| Rankin, C | 1 |
| Toriola, AT | 1 |
| Makar, KW | 1 |
| Altug-Teber, Ö | 1 |
| Benedetti, JK | 1 |
| Holmes, RS | 1 |
| Smalley, SR | 1 |
| Blanke, CD | 1 |
| Lenz, HJ | 3 |
| Kandioler, D | 1 |
| Schoppmann, SF | 1 |
| Zwrtek, R | 1 |
| Kappel, S | 1 |
| Wolf, B | 1 |
| Mittlböck, M | 1 |
| Kührer, I | 1 |
| Hejna, M | 1 |
| Pluschnig, U | 1 |
| Ba-Ssalamah, A | 1 |
| Wrba, F | 1 |
| Zacherl, J | 1 |
| Söderlund Leifler, K | 1 |
| Asklid, A | 1 |
| Fornander, T | 1 |
| Stenmark Askmalm, M | 1 |
| Lee, AM | 1 |
| Shi, Q | 1 |
| Pavey, E | 1 |
| Alberts, SR | 1 |
| Sargent, DJ | 1 |
| Sinicrope, FA | 1 |
| Berenberg, JL | 1 |
| Goldberg, RM | 1 |
| Diasio, RB | 2 |
| Geng, R | 1 |
| Chen, Z | 1 |
| Zhao, X | 1 |
| Qiu, L | 1 |
| Liu, X | 1 |
| Guo, W | 1 |
| He, G | 1 |
| Li, J | 2 |
| Zhu, X | 1 |
| Parvin, S | 1 |
| Ahmed, MU | 1 |
| Bin Sayeed, MS | 1 |
| Uddin, MM | 1 |
| Hussain, SM | 1 |
| Hasnat, A | 1 |
| Balboa-Beltrán, E | 1 |
| Duran, G | 1 |
| Lamas, MJ | 1 |
| Carracedo, A | 1 |
| Barros, F | 1 |
| He, S | 1 |
| Zhao, Z | 1 |
| Yang, Y | 1 |
| O'Connell, D | 1 |
| Zhang, X | 1 |
| Oh, S | 1 |
| Ma, B | 1 |
| Lee, JH | 2 |
| Zhang, T | 1 |
| Varghese, B | 1 |
| Yip, J | 1 |
| Dolatshahi Pirooz, S | 1 |
| Li, M | 1 |
| Zhang, Y | 1 |
| Li, GM | 1 |
| Ellen Martin, S | 1 |
| Machida, K | 1 |
| Liang, C | 1 |
| Kleist, B | 1 |
| Kempa, M | 1 |
| Meurer, T | 1 |
| Poetsch, M | 1 |
| Sebio, A | 1 |
| Matsusaka, S | 1 |
| Zhang, W | 3 |
| Yang, D | 2 |
| Ning, Y | 2 |
| Stremitzer, S | 1 |
| Stintzing, S | 1 |
| Sunakawa, Y | 1 |
| Yamauchi, S | 1 |
| Fujimoto, Y | 1 |
| Ueno, M | 1 |
| Gao, S | 1 |
| Tibiche, C | 1 |
| Zou, J | 1 |
| Zaman, N | 1 |
| Trifiro, M | 1 |
| O'Connor-McCourt, M | 1 |
| Wang, E | 1 |
| Sonke, GS | 1 |
| Deenen, MJ | 2 |
| Froehlich, TK | 1 |
| Amstutz, U | 1 |
| Largiadèr, CR | 1 |
| Jennings, BA | 1 |
| Marinaki, AM | 1 |
| Sanderson, JD | 1 |
| Kleibl, Z | 1 |
| Kleiblova, P | 1 |
| Schwab, M | 2 |
| Zanger, UM | 2 |
| Palles, C | 1 |
| Tomlinson, I | 1 |
| Gross, E | 2 |
| van Kuilenburg, AB | 1 |
| Punt, CJ | 2 |
| Koopman, M | 1 |
| Beijnen, JH | 2 |
| Cats, A | 2 |
| Schellens, JH | 2 |
| Lin, L | 1 |
| Zhang, Z | 1 |
| Wang, L | 1 |
| Wang, J | 1 |
| Koo, SX | 1 |
| Chan, SH | 1 |
| Ngeow, J | 1 |
| Zhao, XQ | 1 |
| Cao, WJ | 1 |
| Yang, HP | 1 |
| Yang, XW | 1 |
| Tang, P | 1 |
| Sun, L | 1 |
| Gao, X | 1 |
| Oh, SY | 2 |
| Shin, A | 1 |
| Kim, SG | 1 |
| Hwang, JA | 2 |
| Hong, SH | 2 |
| Lee, YS | 2 |
| Kwon, HC | 2 |
| de Rosa, N | 1 |
| Rodriguez-Bigas, MA | 1 |
| Chang, GJ | 1 |
| Veerapong, J | 1 |
| Borras, E | 1 |
| Krishnan, S | 1 |
| Bednarski, B | 1 |
| Messick, CA | 1 |
| Skibber, JM | 1 |
| Feig, BW | 1 |
| Lynch, PM | 1 |
| Vilar, E | 1 |
| You, YN | 1 |
| Tecza, K | 1 |
| Pamula-Pilat, J | 1 |
| Lanuszewska, J | 1 |
| Grzybowska, E | 1 |
| Li, CY | 1 |
| Huang, PM | 1 |
| Chu, PY | 1 |
| Chen, PM | 1 |
| Lin, MW | 1 |
| Kuo, SW | 1 |
| Lee, JM | 1 |
| Ying, X | 1 |
| Zhang, L | 1 |
| Xiang, X | 1 |
| Xiong, J | 1 |
| Kweekel, DM | 1 |
| Antonini, NF | 1 |
| Van der Straaten, T | 1 |
| Nortier, JW | 1 |
| Busse, B | 1 |
| Riemenschneider, M | 1 |
| Neubauer, S | 1 |
| Seck, K | 1 |
| Klein, HG | 1 |
| Kiechle, M | 1 |
| Lordick, F | 1 |
| Meindl, A | 1 |
| Muslimov, GF | 1 |
| Kim, YI | 1 |
| George, J | 1 |
| Dharanipragada, K | 1 |
| Krishnamachari, S | 1 |
| Chandrasekaran, A | 1 |
| Sam, SS | 1 |
| Sunder, E | 1 |
| Fernández-Peralta, AM | 1 |
| Daimiel, L | 1 |
| Nejda, N | 1 |
| Iglesias, D | 1 |
| Medina Arana, V | 1 |
| González-Aguilera, JJ | 1 |
| Kopper, L | 1 |
| Tímár, J | 1 |
| Vidaurreta, M | 1 |
| Sánchez-Muñoz, R | 1 |
| Veganzones, S | 1 |
| Rafael, S | 1 |
| Gutiérrez, M | 1 |
| de-la-Orden, V | 1 |
| Fernández, C | 1 |
| Arroyo, M | 1 |
| Cerdán, FJ | 1 |
| Maestro de las Casas, ML | 1 |
| Yao, S | 1 |
| Barlow, WE | 1 |
| Albain, KS | 1 |
| Choi, JY | 1 |
| Zhao, H | 1 |
| Livingston, RB | 1 |
| Davis, W | 1 |
| Rae, JM | 1 |
| Yeh, IT | 1 |
| Hutchins, LF | 1 |
| Ravdin, PM | 1 |
| Martino, S | 1 |
| Lyss, AP | 1 |
| Osborne, CK | 1 |
| Abeloff, MD | 1 |
| Hortobagyi, GN | 1 |
| Hayes, DF | 1 |
| Ambrosone, CB | 1 |
| Fujishima, M | 1 |
| Inui, H | 1 |
| Hashimoto, Y | 1 |
| Azumi, T | 1 |
| Yamamoto, N | 1 |
| Kato, H | 1 |
| Hojo, T | 1 |
| Yamato, M | 1 |
| Matsunami, N | 1 |
| Shiozaki, H | 1 |
| Watatani, M | 1 |
| Okuyama, Y | 1 |
| Hazama, S | 2 |
| Nozawa, H | 1 |
| Kobayashi, M | 1 |
| Takahashi, K | 1 |
| Fujikawa, K | 1 |
| Kato, T | 1 |
| Nagata, N | 1 |
| Kimura, H | 1 |
| Oba, K | 1 |
| Sakamoto, J | 1 |
| Mishima, H | 1 |
| Caronia, D | 1 |
| Martin, M | 1 |
| Sastre, J | 1 |
| de la Torre, J | 1 |
| García-Sáenz, JA | 1 |
| Alonso, MR | 1 |
| Moreno, LT | 1 |
| Pita, G | 1 |
| Díaz-Rubio, E | 1 |
| Benítez, J | 1 |
| González-Neira, A | 1 |
| Fariña-Sarasqueta, A | 1 |
| Gosens, MJ | 1 |
| Moerland, E | 1 |
| van Lijnschoten, I | 1 |
| Lemmens, VE | 1 |
| Slooter, GD | 1 |
| Rutten, HJ | 1 |
| van den Brule, AJ | 1 |
| Gerger, A | 1 |
| Bohanes, P | 1 |
| Winder, T | 1 |
| LaBonte, MJ | 1 |
| Wilson, PM | 1 |
| Benhaim, L | 1 |
| Paez, D | 1 |
| El-Khoueiry, R | 1 |
| El-Khoueiry, A | 1 |
| Kahn, M | 1 |
| Crea, F | 1 |
| Fornaro, L | 1 |
| Paolicchi, E | 1 |
| Masi, G | 1 |
| Frumento, P | 1 |
| Loupakis, F | 1 |
| Salvatore, L | 1 |
| Cremolini, C | 1 |
| Schirripa, M | 1 |
| Graziano, F | 1 |
| Ronzoni, M | 1 |
| Ricci, V | 1 |
| Farrar, WL | 1 |
| Falcone, A | 1 |
| Danesi, R | 1 |
| Kemmerich, K | 1 |
| Dingler, FA | 1 |
| Rada, C | 1 |
| Neuberger, MS | 1 |
| Przybylowska-Sygut, K | 1 |
| Stanczyk, M | 1 |
| Kusinska, R | 1 |
| Kordek, R | 1 |
| Majsterek, I | 1 |
| Ye, S | 1 |
| Rong, J | 1 |
| Huang, SH | 1 |
| Zheng, ZS | 1 |
| Yun, M | 1 |
| Wang, SM | 1 |
| Bai, YL | 1 |
| Zhou, B | 1 |
| Jing, XY | 1 |
| Zhang, B | 1 |
| Huo, XQ | 1 |
| Ma, C | 1 |
| He, JM | 1 |
| Kim, SH | 1 |
| Lee, S | 1 |
| Graves, CA | 1 |
| Camphausen, K | 1 |
| Kim, HJ | 1 |
| Zhu, L | 1 |
| Wang, F | 1 |
| Hu, F | 1 |
| Wang, Y | 2 |
| Li, D | 1 |
| Dong, X | 1 |
| Cui, B | 1 |
| Zhao, Y | 1 |
| Oka, M | 1 |
| Hinoda, Y | 1 |
| de Vos tot Nederveen Cappel, WH | 1 |
| Meulenbeld, HJ | 1 |
| Kleibeuker, JH | 1 |
| Nagengast, FM | 1 |
| Menko, FH | 1 |
| Griffioen, G | 1 |
| Morreau, H | 1 |
| Vasen, HF | 1 |
| Lazar, A | 1 |
| Mau-Holzmann, UA | 1 |
| Kolb, H | 1 |
| Reichenmiller, HE | 1 |
| Riess, O | 1 |
| Schömig, E | 1 |
| Merk, HF | 1 |
| Altundag, O | 1 |
| Altundag, K | 1 |
| Silay, K | 1 |
| Turen, S | 1 |
| Hoehn, S | 1 |
| Wolschke, C | 1 |
| Wittmer, C | 1 |
| Stueber, C | 1 |
| Hossfeld, DK | 1 |
| Stoehlmacher, J | 1 |
| Sarbia, M | 1 |
| Stahl, M | 1 |
| von Weyhern, C | 1 |
| Weirich, G | 1 |
| Pühringer-Oppermann, F | 1 |
| Chen, L | 1 |
| Fan, Y | 1 |
| Lang, RG | 1 |
| Guo, XJ | 1 |
| Sun, YL | 1 |
| Fu, L | 1 |
| Ezzeldin, HH | 1 |
| Marx, C | 1 |
| Schaeffeler, E | 1 |
| Klein, K | 1 |
| Dippon, J | 1 |
| Kerb, R | 1 |
| Blievernicht, J | 1 |
| Fischer, J | 1 |
| Hofmann, U | 1 |
| Bokemeyer, C | 1 |
| Eichelbaum, M | 1 |
| Xu, JM | 1 |
| Shen, L | 1 |
| Xu, N | 1 |
| Wang, JW | 1 |
| Jiao, SC | 1 |
| Zhang, JS | 1 |
| Song, ST | 1 |
| Bao, HY | 1 |
| Yang, L | 1 |
| Li, F | 1 |
| Nordgard, SH | 1 |
| Alnaes, GI | 1 |
| Hihn, B | 1 |
| Lingjaerde, OC | 1 |
| Liestøl, K | 1 |
| Tsalenko, A | 1 |
| Sørlie, T | 1 |
| Lønning, PE | 1 |
| Børresen-Dale, AL | 1 |
| Kristensen, VN | 1 |
| Lucchinetti, CF | 1 |
| Kimmel, DW | 1 |
| Pavelko, K | 1 |
| Rodriguez, M | 1 |
| Potter, JD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Association of the C677T and A1298C MTHFR Polymorphisms With Chemotherapy Effectiveness Among Patients With Metastatic Colorectal Cancer[NCT03852290] | 65 participants (Anticipated) | Observational | 2019-01-16 | Active, not recruiting | |||
| Associations Between Genetic Polymorphisms of Drug Transporter Genes and Toxicity of Doxorubicin and Cyclophosphamide Chemotherapy in Breast Cancer Patients[NCT04654195] | 100 participants (Anticipated) | Observational | 2020-12-01 | Recruiting | |||
| Pharmacogenetics in Relation to Breast Cancer Outcomes in SWOG 8897[NCT00896623] | 1,577 participants (Actual) | Observational | 2006-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for fluorouracil and Genetic Predisposition
| Article | Year |
|---|---|
The correlation of leukocyte-specific protein 1 (LSP1) rs3817198(T>C) polymorphism with breast cancer: A meta-analysis.
Topics: Breast Neoplasms; Cisplatin; Doxorubicin; Female; Fluorouracil; Genetic Predisposition to Disease; H | 2022 |
The correlation of leukocyte-specific protein 1 (LSP1) rs3817198(T>C) polymorphism with breast cancer: A meta-analysis.
Topics: Breast Neoplasms; Cisplatin; Doxorubicin; Female; Fluorouracil; Genetic Predisposition to Disease; H | 2022 |
The correlation of leukocyte-specific protein 1 (LSP1) rs3817198(T>C) polymorphism with breast cancer: A meta-analysis.
Topics: Breast Neoplasms; Cisplatin; Doxorubicin; Female; Fluorouracil; Genetic Predisposition to Disease; H | 2022 |
The correlation of leukocyte-specific protein 1 (LSP1) rs3817198(T>C) polymorphism with breast cancer: A meta-analysis.
Topics: Breast Neoplasms; Cisplatin; Doxorubicin; Female; Fluorouracil; Genetic Predisposition to Disease; H | 2022 |
The correlation of leukocyte-specific protein 1 (LSP1) rs3817198(T>C) polymorphism with breast cancer: A meta-analysis.
Topics: Breast Neoplasms; Cisplatin; Doxorubicin; Female; Fluorouracil; Genetic Predisposition to Disease; H | 2022 |
The correlation of leukocyte-specific protein 1 (LSP1) rs3817198(T>C) polymorphism with breast cancer: A meta-analysis.
Topics: Breast Neoplasms; Cisplatin; Doxorubicin; Female; Fluorouracil; Genetic Predisposition to Disease; H | 2022 |
The correlation of leukocyte-specific protein 1 (LSP1) rs3817198(T>C) polymorphism with breast cancer: A meta-analysis.
Topics: Breast Neoplasms; Cisplatin; Doxorubicin; Female; Fluorouracil; Genetic Predisposition to Disease; H | 2022 |
The correlation of leukocyte-specific protein 1 (LSP1) rs3817198(T>C) polymorphism with breast cancer: A meta-analysis.
Topics: Breast Neoplasms; Cisplatin; Doxorubicin; Female; Fluorouracil; Genetic Predisposition to Disease; H | 2022 |
The correlation of leukocyte-specific protein 1 (LSP1) rs3817198(T>C) polymorphism with breast cancer: A meta-analysis.
Topics: Breast Neoplasms; Cisplatin; Doxorubicin; Female; Fluorouracil; Genetic Predisposition to Disease; H | 2022 |
Nowadays pancreatic cancer prognosis.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; C | 2019 |
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gas | 2015 |
Role of the MTHFR polymorphisms in cancer risk modification and treatment.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Fluorouracil; Folic Acid; Genetic Predisposition t | 2009 |
[Polymorphism in colorectal cancer].
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genetic Predisposition to D | 2003 |
[Pharmacogenetics: Important aspects for dermatology].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Dapsone; Dermatology; Drug Eruptions; Fluorou | 2005 |
9 trials available for fluorouracil and Genetic Predisposition
| Article | Year |
|---|---|
[Impact of CCND1 A870G polymorphism on acute adverse events in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2013 |
Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304).
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Fluorouracil; Folic Acid; Genetic Ass | 2014 |
The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Biomarkers, Tumor; Ca | 2014 |
The RAD51 135G>C polymorphism is related to the effect of adjuvant therapy in early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2015 |
DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Codon; | 2009 |
Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ch | 2010 |
Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal | 2011 |
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
Topics: Antimetabolites, Antineoplastic; Diarrhea; Dihydrouracil Dehydrogenase (NADP); DNA Methylation; Fema | 2008 |
57 other studies available for fluorouracil and Genetic Predisposition
| Article | Year |
|---|---|
Natural Compounds or Their Derivatives against Breast Cancer: A Computational Study.
Topics: Apigenin; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Citrinin; Curcumin; Female; Fluorouracil; | 2022 |
Colorectal cancer in Lynch syndrome associated with PMS2 and MSH6 mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms, Hereditary | 2020 |
Glutathione S-transferase Polymorphisms in Head and Neck Squamous Cell Carcinoma Treated with Chemotherapy and/or Radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2020 |
Complete Response to Chemotherapy in Metastatic Pancreatic Carcinoma Associated with Double Heterozygous Germline Mutation in BRCA2 and CHEK2 Genes - a Case Report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BRCA2 Protein; Checkpoint Kinase 2; | 2020 |
C677T and A1298C MTHFR gene polymorphisms and response to fluoropyrimidine-based chemotherapy in Mestizo patients with metastatic colorectal cancer.
Topics: Case-Control Studies; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Genetic Predisposition | 2021 |
MicroRNA-binding site polymorphisms in genes involved in colorectal cancer etiopathogenesis and their impact on disease prognosis.
Topics: 3' Untranslated Regions; Adenomatous Polyposis Coli Protein; Aged; Antimetabolites, Antineoplastic; | 2017 |
Short article: Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2018 |
Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Capecitabine; Chemoradioth | 2018 |
Impact of protocol change on individual factors related to course of adverse reactions to chemotherapy for breast cancer.
Topics: Abdominal Pain; Adult; Aged; Alcohol Oxidoreductases; Antineoplastic Combined Chemotherapy Protocols | 2020 |
An experimental study to identify the potential role of pharmacogenomics in determining the occurrence of oxaliplatin-induced liver injury.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Combined Chemotherapy Protocols; Cation Transport | 2013 |
TNF-α gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 2013 |
Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2013 |
A rare cause of susceptibility to neutropenic sepsis in a patient with metastatic pancreas cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Ind | 2014 |
Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy.
Topics: Aged; Alleles; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aryldialkylpho | 2014 |
Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients.
Topics: Adult; Aged; Bangladesh; Biomarkers, Pharmacological; Breast Neoplasms; Cyclophosphamide; Epirubicin | 2015 |
Long Survival and Severe Toxicity Under 5-Fluorouracil-Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Fluorouracil; Gene Frequency; Genet | 2015 |
Truncating mutation in the autophagy gene UVRAG confers oncogenic properties and chemosensitivity in colorectal cancers.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Autophagy; Carcinogenesis; Cell Line, Tumor; | 2015 |
Correlation between DPYD gene variation and KRAS wild type status in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil | 2016 |
Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer.
Topics: Acyltransferases; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; California; Chemotherapy | 2016 |
Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2016 |
Roles of genetic variants in the PI3K/PTEN pathways in susceptibility to colorectal carcinoma and clinical outcomes treated with FOLFOX regimen.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Class I | 2015 |
Genetic predisposition resulting in sinusoidal obstruction syndrome in a patient with resected sigmoid cancer on adjuvant oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; | 2016 |
DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dihydrouracil Dehydrogenase | 2016 |
Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Gene Frequency; G | 2016 |
DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benchmarking; Biomarkers, Tumor; Chemoradioth | 2016 |
Genetic polymorphisms and response to 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 2016 |
Predictors of Survival in Esophageal Squamous Cell Carcinoma with Pathologic Major Response after Neoadjuvant Chemoradiation Therapy and Surgery: The Impact of Chemotherapy Protocols.
Topics: Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease Pro | 2016 |
Influence of TS and ABCB1 gene polymorphisms on survival outcomes of 5‑FU-based chemotherapy in a Chinese population of advanced gastric cancer patients.
Topics: Adult; Aged; ATP Binding Cassette Transporter, Subfamily B; Biomarkers, Tumor; China; Female; Fluoro | 2017 |
Is fluorouracil-induced severe toxicity in DPYD*2A individuals related to sex or to treatment regimen?
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and A | 2008 |
Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Case-Control | 2008 |
Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Proliferation; Drug Evaluation, Preclinical; Epide | 2008 |
A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Al | 2009 |
Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2010 |
[Validation study of KRAS mutation in colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Vascular endothelial growth factor gene polymorphisms in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2010 |
Relationship between thymidylate synthase (TYMS) gene polymorphism and TYMS protein levels in patients with high-risk breast cancer.
Topics: 3' Untranslated Regions; 5' Untranslated Regions; Breast Neoplasms; Drug Screening Assays, Antitumor | 2010 |
A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Base Sequence; Binding Sites; Breas | 2011 |
TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.
Topics: 5' Untranslated Regions; Age Distribution; Aged; Biomarkers, Tumor; Colonic Neoplasms; Female; Fluor | 2011 |
Common cancer stem cell gene variants predict colon cancer recurrence.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo | 2011 |
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2012 |
Germline ablation of SMUG1 DNA glycosylase causes loss of 5-hydroxymethyluracil- and UNG-backup uracil-excision activities and increases cancer predisposition of Ung-/-Msh2-/- mice.
Topics: Animals; beta-Galactosidase; Cell Line; DNA Repair; Fibroblasts; Fluorouracil; Gene Targeting; Genet | 2012 |
Association of the Arg194Trp and the Arg399Gln polymorphisms of the XRCC1 gene with risk occurrence and the response to adjuvant therapy among Polish women with breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2013 |
XRCC1 and ADPRT polymorphisms associated with survival in breast cancer cases treated with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; DNA-Binding Prot | 2012 |
Predictive role of GSTs on the prognosis of breast cancer patients with neoadjuvant chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Child; Cyclopho | 2012 |
The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chi- | 2013 |
Association between MTHFR polymorphisms and overall survival of colorectal cancer patients in Northeast China.
Topics: Aged; Asian People; Chemotherapy, Adjuvant; China; Colorectal Neoplasms; Female; Fluorouracil; Follo | 2013 |
Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer.
Topics: Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorectal Neoplasms, Hered | 2004 |
Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Cecal Neoplasms; Dihydropyrimidine Dehydrogenase Defic | 2004 |
Gender differences in the dihydropyrimidine dehydrogenase expression may contribute to higher toxicity in women treated with 5-fluorouracil therapy.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydro | 2005 |
Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2006 |
The prognostic significance of genetic polymorphisms (Methylenetetrahydrofolate Reductase C677T, Methionine Synthase A2756G, Thymidilate Synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma.
Topics: 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; Antineoplastic Agents; Combined Modality | 2006 |
[Diagnosis and prognosis study of breast carcinoma with micropapillary component].
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone N | 2007 |
Predicting fluorouracil toxicity: can we finally do it?
Topics: Antimetabolites, Antineoplastic; Diarrhea; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genetic | 2008 |
[Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian Peop | 2007 |
Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibiotics, Antineoplastic; Antimetabolites, | 2008 |
5-Fluorouracil and levamisole exacerbate demyelination in susceptible mice infected with Theiler's virus.
Topics: Adjuvants, Immunologic; Animals; Antimetabolites, Antineoplastic; Demyelinating Diseases; Female; Fl | 1997 |
Thymidylate synthase polymorphism and survival of colorectal cancer patients treated with 5-fluorouracil.
Topics: Colorectal Neoplasms; Fluorouracil; Genetic Predisposition to Disease; Polymorphism, Genetic; Progno | 2002 |